Roger Adsett Sells 2,444 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 2,444 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80. Following the transaction, the chief operating officer now owns 147,666 shares in the company, valued at approximately $9,738,572.70. This trade represents a 1.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total value of $312,159.36.

Insmed Trading Down 0.7 %

Shares of INSM stock traded down $0.47 during trading hours on Friday, reaching $65.25. 3,087,759 shares of the stock were exchanged, compared to its average volume of 1,881,810. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The firm has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. The company’s 50-day moving average price is $71.29 and its 200-day moving average price is $72.44.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter last year, the company posted ($1.10) earnings per share. The business’s revenue was up 18.1% on a year-over-year basis. As a group, equities analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Trading of Insmed

Large investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC bought a new stake in Insmed during the 3rd quarter valued at about $30,000. GAMMA Investing LLC grew its stake in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the period. Blue Trust Inc. raised its position in Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. purchased a new stake in shares of Insmed in the 3rd quarter worth $133,000.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INSM. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Bank of America increased their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.